{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:36:43Z","timestamp":1791380203061,"version":"4.3.3"},"reference-count":27,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nMemenatine is USFDA approved for dementia of Alzheimer\u2019s disease. Apart from this indication, trend of its use in psychiatry is on the rise addressing a multitude of disorders.\nStudy question\nMemantine remains one of only few psychotropic drugs with antiglutamate activity. This might impart it a therapeutic potential in treatment-resistant major psychiatric disorders characterized by neuroprogression. We reviewed memantine basic pharmacology and its diversifying clinical indications while examining the extant evidence.\nMethods\nEMBASE, Ovid MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Database of Systemic Reviews were searched for all relevant studies up to date of November, 2022.\nResults\nSound evidence supports use of memantine for major neuro-cognitive disorder due to Alzheimer\u2019s disease and severe vascular dementia, obsessive-compulsive disorder, treatment-resistant schizophrenia, and, ADHD. Modicum evidence supports use of memantine for PTSD, GAD and pathological gambling. Less compelling evidence is present for use in catatonia. No evidence supports use for core symptoms of autism spectrum disorder.\nConclusions\nMemantine is an important addition to the psychopharmacological armamentarium. Level of evidence supporting the use of memantine in these off-label indications is highly variable, and hence, sound clinical judgment is necessary for its proper use and placement in real-life psychiatric practice and psychopharmacotherapy algorithms.<\/jats:p>","DOI":"10.64719\/pb.4459","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"30-38","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Indications of Memantine in Psychiatry-Science or Art?"],"prefix":"10.64719","volume":"53","author":[{"given":"Muhammad","family":"Aljuwaiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadyah","family":"Alayadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ozidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenouda Anwar Shafik","family":"Zakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Rushdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Naguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Song X, Jensen MO, Jogini V et al. Mechanism of NMDA Receptor Channel Block by MK-801 and Memantine. Nature. 2018;556(7702):515\u2013519.","DOI":"10.1038\/s41586-018-0039-9"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"McShane R, Westby MJ, Roberts E et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;(3):CD003154.","DOI":"10.1002\/14651858.CD003154.pub6"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Brignell A, Marraffa C, Williams K et al. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022;8(8):CD013845.","DOI":"10.1002\/14651858.CD013845.pub2"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Naguy A, Alenezi S, Alwetayan S. Acamprosate for Treatment-Refractory Catatonia. Am J Ther. 2020;27(3):e324\u2013e326.","DOI":"10.1097\/MJT.0000000000000991"},{"key":"ref5","unstructured":"Hasoglu T, Francis A, Mormando C. Electroconvulsive Therapy-Resistant Catatonia: Case Report and Literature Review. J Acad Consult Liaison Psychiatry. 2022;S2667\u20132960(22):00295\u20136."},{"key":"ref6","unstructured":"Chaffkin J, Josephs IA, Katz ER. Safe Use of Memantine in a Pediatric Patient With Catatonia. J Am Acad Child Adolesc Psychiatry. 2022;S0890\u20138567(22):00292\u20131."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Naguy A, Pridmore S, Alamiri B. COVID delirium-psychopharmacological tips. CNS Spectr. 2021 doi: 10.1017\/S1092852921000286. 1\u20132. doi:","DOI":"10.1017\/S1092852921000286"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B. Treatment-resistant OCD-A psychopharmacological \u2018touche d\u2019art\u2019. Asian J Psychiatr. 2018;34:98\u201399.","DOI":"10.1016\/j.ajp.2018.04.025"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Modarressi A, Chaibakhsh S, Koulaeinejad N et al. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602.","DOI":"10.1016\/j.psychres.2019.112602"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Naguy A, Alrashidi F. Step-wise Drug Therapy for Comorbid Bipolar and Obsessive-Compulsive Disorders. Am J Ther. 2019;26(5):e668\u2013e670.","DOI":"10.1097\/MJT.0000000000000872"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lu R-B, Wang T-Y, Lee S-Y et al. Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients. J Affect Disord. 2021;279:229\u2013238.","DOI":"10.1016\/j.jad.2020.10.003"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B. Ultra-Treatment Resistant Schizophrenia-Where Do We Stand. Asian J psychiatry. 2019;44:95\u201396.","DOI":"10.1016\/j.ajp.2019.07.028"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Andrade C. Memantine as an Augmentation Treatment for Schizophrenia: Limitations of Meta-Analysis for Evidence-Based Evaluation of Research. J Clin Psychiatry. 2017;78(9):e1307\u2013e1309.","DOI":"10.4088\/JCP.17f11998"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Naguy A, El-Sheshaie A, Elsori DH et al. Solriamfetol for attention deficit hyperactivity disorder. CNS Spectr. 2021 doi: 10.1017\/S1092852921000328. 1\u20132. doi:","DOI":"10.1017\/S1092852921000328"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mohammadzadeh S, Ahangari TK, Yousefi F. The effect of memantine in adult patients with attention deficit hyperactivity disorder. Hum Psychopharmacol. 2019;34(1):e2687.","DOI":"10.1002\/hup.2687"},{"key":"ref16","unstructured":"Mohammadi MR, Mohammadzadeh S, Akhondzadeh S. Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial. Iran J Psychiatry. 2015;10(2):106\u2013114."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Smith KL, Rao RR, Velazquez-Sanchez C et al. The uncompetitive N-methyl-D-aspartate antagonist memantine reduces binge-like eating, food-seeking behavior, and compulsive eating: role of the nucleus accumbens shell. Neuropsychopharmacology. 2015;40:1163\u20131171.","DOI":"10.1038\/npp.2014.299"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lijffijt M, Green CE, Balderston N et al. A proof-of-mechanism study to test effects of the NMDA receptor antagonist lanicemine on behavioral sensitization in individuals with symptoms of PTSD. Frontiers in Psychiatry. 2019;10:846.","DOI":"10.3389\/fpsyt.2019.00846"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B. PTSD-Inevitable or preventable. Australas Psychiatry. 2018;26(6):670.","DOI":"10.1177\/1039856218783853"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Montemitro C, Angerbrandt A, Wang T-Y et al. Mechanistic insights into the efficacy of memantine in treating certain drug addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110409.","DOI":"10.1016\/j.pnpbp.2021.110409"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Marvanova M, Lakso M, Prihonen J et al. The Neuroprotective Agent Memantine Induces Brain-Derived Neurotrophic Factor and trkB Receptor Expression in Rat Brain. Mol Cell Neurosci. 2001;18(3):247\u2013258.","DOI":"10.1006\/mcne.2001.1027"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Karolczak D, Sawicka E, Dorszewska J et al. Memantine\u2013neuroprotective drug in aging brain. Pol J Pathol. 2013;64(3):196\u2013203.","DOI":"10.5114\/pjp.2013.38139"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Grant JE, Chamberlain SR, Odlaug BL et al. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl). 2010;12(4):603\u2013612.","DOI":"10.1007\/s00213-010-1994-5"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Thomas A, Bonanni L, Gambi F et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68:400\u2013404.","DOI":"10.1002\/ana.22029"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Schwartz TL, Siddiqui UA, Raza S. Memantine as an augmentation therapy for anxiety disorders. Case Rep Psychiatry. 2012;2012:749796.","DOI":"10.1155\/2012\/749796"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Nair AS, Sahoo RK. Efficacy of Memantine Hydrochloride in Neuropathic Pain. Indian J Palliat Care. 2019;25(1):161\u2013161.","DOI":"10.4103\/IJPC.IJPC_215_18"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"McCarberg B, Barkin RL, Zaleon C. The Management of Neuropathic Pain With a Focus Upon Older Adults. Am J Ther. 2012;19(3):211\u2013227.","DOI":"10.1097\/MJT.0b013e31822119b3"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:31:35Z","timestamp":1791315095000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/clinical-indications-of-memantine-in-psychiatry-science-or-art\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4459","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}